

**CLAIMS**

1. A method of screening for and /or diagnosis of a cardiovascular disorder in a subject, comprising the steps of:

- 5           i)       detecting and /or quantifying the level of a polypeptide in a biological sample from said subject, wherein the polypeptide is selected from:
- a.   a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4;
- 10           b.   a variant, with at least 75% sequence identity, having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4; and
- c.   a fragment of a polypeptide as defined in i) or ii) above which is a least seven amino acids long; and
- ii)     comparing said level to that of a control sample,
- 15       wherein an increase in said level relative to that of the control is indicative of a cardiovascular disorder.

2. A method of predicting a cardiovascular disorder in a subject, comprising the steps of:

- 20           i)       detecting and /or quantifying the level of a polypeptide in a biological sample from said subject, wherein the polypeptide is selected from:
- a.   a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4;
- b.   a variant, with at least 75% sequence identity, having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence of SEQ ID
- 25           NO:2 or SEQ ID NO:4; and
- c.   a fragment of a polypeptide as defined in i) or ii) above which is a least seven amino acids long; and
- ii)     comparing said level to that of a control sample,
- wherein an increase in said level relative to that of the control indicates a risk of developing a
- 30       cardiovascular disorder.

3. The method of claim 1 or 2, wherein said cardiovascular disorder is Coronary Artery Disease (CAD).

4. The method of any one of claims 1-3, wherein said biological sample is plasma.
5. The method of any one of claims 1-4, wherein said polypeptide is detected and /or quantified by mass spectrometry.
- 5
6. The method of any one of claims 1 to 4, wherein said polypeptide is detected and /or quantified by Enzyme-Linked Immuno Sorbent Assay.
7. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of:
- 10
- i) SEQ ID NOs:1-10 ; and
  - ii) a variant of (i), with at least 75% sequence identity, having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence of (i).
- 15
8. The polypeptide of claim 7, wherein said polypeptide is fused to a heterologous polypeptide sequence.
9. An anti-Cardiovascular disorder Plasma Polypeptide (CPP) antibody that selectively binds to a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID
- 20
- NOs:1-10.
10. A method of binding an antibody to a Cardiovascular disorder Plasma Polypeptide (CPP) comprising the steps of:
- i) contacting the antibody of claim 9 with a biological sample under conditions that permit
  - 25 antibody binding; and
  - ii) removing contaminants.
11. The method of claim 10, wherein said antibody is attached to a label group.
- 30
12. The method of claim 10, wherein said sample is human plasma.
13. A method of identifying a Cardiovascular disorder Plasma Polypeptide (CPP) modulator comprising the steps of:
- i) contacting a test compound with a polypeptide selected from the group consisting of

SEQ ID NOs:1-10 under sample conditions permissive for at least one CPP biological activity;

- ii) determining the level of said at least one CPP biological activity;
- iii) comparing said level to that of a control sample lacking said test compound; and
- iv) selecting a test compound which causes said level to change for further testing as a CPP modulator for the prophylactic and/or therapeutic treatment of cardiovascular disorders.

5